Akebia Therapeutics Inc (NASDAQ:AKBA) The 6 analysts offering 12-month price forecasts for Akebia Therapeutics Inc have a median target of 6.50, with a high estimate of 10.00 and a low estimate of 6.00. The median estimate represents a +238.54% increase from the last price of 1.92.
Is Akebia Therapeutics a buy?
Fair opening price Current price
----------------------------------- ------------------
$1.87 $1.91 (Overvalued)
Who owns AKBA stock?
Stockholder Stake Shares owned
-------------------------------- ----- ------------
BlackRock Fund Advisors 6.97% 12,199,161
The Vanguard Group, Inc. 6.89% 12,057,702
Marshall Wace LLP 3.98% 6,968,811
Nantahala Capital Management LLC 2.85% 4,978,195
Why is AKBA stock down?
Shares of Akebia Therapeutics (NASDAQ: AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a late-stage study of vadadustat in treating anemia due to chronic kidney disease (CKD) in adult patients not on dialysis.3 Sept 2020
Is AKBA a good investment?
The financial health and growth prospects of AKBA, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Is Qualigen Therapeutics a good stock to buy?
Qualigen Therapeutics has received a consensus rating of Buy.
Is Applied Therapeutics a buy?
Applied Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.